Covalent BTK Inhibitors: A Review of the Evidence in Chronic Lymphocytic Leukemia

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.